Patent ID: 8513275

Claim:
A rifaximin polymorph Form kappa, a rifaximin polymorph Form theta, a rifaximin:piperazine cocrystal 1 or a rifaximin:piperazine cocrystal 2 wherein: the polymorph Form kappa exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ at 6.45-6.67, 6.83-6.94 and 7.68-7.78; 6.45-6.67, 6.83-6.94 and 18.46-18.61; 6.45-6.67, 6.83-6.94 and 7.52-7.56; 6.83-6.94, 7.68-7.78 and 18.46-18.61; 6.45-6.67, 6.83-6.94, 7.68-7.78 and 18.46-18.61; 6.83-6.94, 7.52-7.56, 7.68-7.78 and 18.46-18.61; 6.45-6.67, 6.83-6.94, 7.52-7.56, 7.68-7.78 and 18.46-18.61; 6.45-6.67, 6.83-6.94, 7.52-7.56, 7.68-7.78, 8.30-8.34 and 18.46-18.61; or 5.41-5.65, 6.45-6.67, 6.83-6.94, 7.52-7.56, 7.68-7.78, 8.30-8.34 and 18.46-18.61; the polymorph Form theta exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ at 5.48, 7.00, 7.75, 8.72, 9.09, or 10.96; 5.48, 7.00, 7.75, 8.72, 9.09, and 10.96; 5.48, 7.00, 7.75, or 5.48, 7.75, and 8.72; 5.48, 7.00, and 8.72; 5.48, 8.72, and 9.09; 5.48, 9.09, and 10.96; 7.75, 8.72, and 9.09; 7.00, 7.75, 8.72, and 10.96; 8.72, 9.09, and 10.96; 7.00, 7.75, 8.72, and 10.96; or 7.00, 8.72, and 10.96; the rifaximin:piperazine cocrystal 1 exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ at 5.74, 6.58, 7.49, 8.21, and 9.83; 5.74, 7.49, 8.21, and 9.83; 5.74, 6.58, 8.21, and 9.83; 5.74, 6.58, 7.49, and 9.83; or 5.74, 6.58, 7.49, and 8.21; and the rifaximin:piperazine cocrystal 2 exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ at 3.64, 5.58, 6.45, 7.29, 7.60, 8.27, and 9.01; 5.58, 6.45, 7.29, 7.60, 8.27, and 9.01; 3.64, 6.45, 7.29, 7.60, 8.27, and 9.01; 3.64, 5.58, 7.29, 7.60, 8.27, and 9.01; 3.64, 5.58, 6.45, 7.60, 8.27, and 9.01; 3.64, 5.58, 6.45, 7.29, 7.60, and 9.01; 3.64, 5.58, 6.45, 7.29, 7.60, and 8.27; or 3.64, 5.58, 6.45, 7.29, and 7.60.